A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Objective Response Rate (ORR)

Objective response is defined as the best overall response of complete response (CR) or partial response (PR), based on RECIST v1.1, per BICR.

Time frame: From Baseline up to end of study (EOS) (approximately 5.5 years)

Change in Quality-of-Life Questionnaire Core 30 (QLQ-C30) Dyspnea Domain Score

Time frame: From Baseline to Week 12

Change in Quality-of-Life Questionnaire Lung Cancer 13 (QLQ-LC13) Symptoms of Dyspnea Subscale

Time frame: From Baseline to Week 12

Change in QLQ-LC13 Symptoms of Cough Subscale

Time frame: From Baseline to Week 12

Change in QLQ-LC13 Symptoms of Chest Pain Subscale

Time frame: From Baseline to Week 12

Change in Physical Function as Measured by QLQ-C30

Time frame: From Baseline to Week 12

Change in Global Health Status as Measured by QLQ-C30

Time frame: From Baseline to Week 12

Progression-free Survival 2 (PFS2)

PFS2 is defined as the time from randomization to progression per investigator after initiation of new anticancer therapy or death from any cause, whichever occurs first.

Time frame: From Baseline up to EOS (approximately 5.5 years)

Change in QLQ-LC13 Subscale Scores

Time frame: From Baseline up to EOS (approximately 5.5 years)

Change in QLQ-C30 Subscale Scores

Time frame: From Baseline up to EOS (approximately 5.5 years)

Time to Deterioration in QLC-LC13 Subscale Scores

Time frame: From Baseline to Week 12

Time to Deterioration in QLC-C30 Subscale Scores

Time frame: From Baseline to Week 12

Change in Summary Scores and Visual Analogue Scale (VAS) Scores

Measured by EuroQol-5 Dimension (EQ-5D-5L).

Time frame: From Baseline up to EOS (approximately 5.5 years)

Duration of Response

Duration of response is defined as the time from the first documentation of objective response until the first documentation of disease progression per BICR or death due to any cause, whichever occurs first.

Time frame: From Baseline up to EOS (approximately 5.5 years)

Time to Response

Defined as the time from randomization to first evidence of PR or CR per BICR.

Time frame: From Baseline up to EOS (approximately 5.5 years)

Disease Control

Defined as CR plus PR plus stable disease based on RECIST v1.1 per BICR.

Time frame: From Baseline up to EOS (approximately 5.5 years)

PFS

Based on investigator tumor assessments per RECIST v1.1.

Time frame: From Baseline up to EOS (approximately 5.5 years)

Objective Response

Based on investigator tumor assessments per RECIST v1.1.

Time frame: From Baseline up to EOS (approximately 5.5 years)

Number of Participants With Treatment-Emergent Adverse Events

Time frame: From Baseline up to EOS (approximately 5.5 years)

Number of Participants With Clinically Significant Changes in Vital Signs

Time frame: From Baseline up to EOS (approximately 5.5 years)

Number of Participants With Clinically Significant Changes in Clinical Laboratory Tests

Time frame: From Baseline up to EOS (approximately 5.5 years)

Maximum Plasma Concentration (Cmax) of Sotorasib

Time frame: Pre-dose Day 1 up to Day 64

Minimum Plasma Concentration (Cmin) of Sotorasib

Time frame: Pre-dose Day 1 up to Day 64

Area Under The Curve (AUC) of Sotorasib

Time frame: Pre-dose Day 1 up to Day 64